{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:25:31Z","timestamp":1792074331211,"version":"4.4.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1097\/rlu.0b013e31824d24fa","type":"journal-article","created":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T01:42:30Z","timestamp":1339551750000},"page":"649-655","source":"Crossref","is-referenced-by-count":40,"title":["Carcinoma Endometrium"],"prefix":"10.1097","volume":"37","author":[{"given":"Punit","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Jeph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daya Nand","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekhar","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210204","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0090-8258(91)90086-K","article-title":". Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.","volume":"40","author":"Morrow","year":"1991","journal-title":"Gynecol Oncol"},{"key":"R2-3-20210204","first-page":"173","article-title":"Advances in the management of endometrial adenocarcinoma. A review.","volume":"47","author":"Irvin","year":"2002","journal-title":"J Reprod Med"},{"key":"R3-3-20210204","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0090-8258(84)90063-5","article-title":"Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients.","volume":"17","author":"Aalders","year":"1984","journal-title":"Gynecol Oncol"},{"key":"R4-3-20210204","first-page":"639","article-title":"Management of recurrent endometrial cancer.","volume":"27","author":"Kao","year":"2004","journal-title":"Chang Gung Med J"},{"key":"R6-3-20210204","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","article-title":". FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology.","volume":"70","author":"Benedet","year":"2000","journal-title":"Int J Gynaecol Obstet"},{"key":"R7-3-20210204","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/gyno.1996.0276","article-title":". Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer.","volume":"63","author":"Jeyarajah","year":"1996","journal-title":"Gynecol Oncol"},{"key":"R8-3-20210204","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.1991.9.6.1071","article-title":". Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions.","volume":"9","author":"Moore","year":"1991","journal-title":"J Clin Oncol"},{"key":"R9-3-20210204","first-page":"654","article-title":". Radical resection and intraoperative radiotherapy for a recurrent endometrial cancer after prolonged remission following aggressive salvage therapy: case report.","volume":"22","author":"Huang","year":"1999","journal-title":"Chang Gung Med J"},{"key":"R10-3-20210204","first-page":"692","article-title":". Computed tomography in endometrial carcinoma.","volume":"95","author":"Connor","year":"2000","journal-title":"Obstet Gynecol"},{"key":"R11-3-20210204","first-page":"315","article-title":". The value of serum CA 125 and association CA 125CA 19-9 in endometrial carcinoma.","volume":"20","author":"Cherchi","year":"1999","journal-title":"Eur J Gynaecol Oncol"},{"key":"R12-3-20210204","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1148\/radiol.2312021184","article-title":". Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning.","volume":"231","author":"Manfredi","year":"2004","journal-title":"Radiology"},{"key":"R13-3-20210204","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1148\/radiology.204.1.9205223","article-title":". Differentiation between recurrent tumor and benign conditions after treatment of gynecologic pelvic carcinoma: value of dynamic contrast-enhanced subtraction MR imaging.","volume":"204","author":"Kinkel","year":"1997","journal-title":"Radiology"},{"key":"R14-3-20210204","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1095-0397(01)00055-3","article-title":". Combined PETCT Imaging in Oncology. Impact on Patient Management.","volume":"3","author":"Kluetz","year":"2000","journal-title":"Clin Positron Imaging"},{"key":"R15-3-20210204","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2003.01.102","article-title":". Value of dual-phase 2-fluoro-2-deoxy-D-glucose positron emission tomography in cervical cancer.","volume":"21","author":"Yen","year":"2003","journal-title":"J Clin Oncol"},{"key":"R16-3-20210204","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1006\/gyno.2001.6386","article-title":". 2-lsqbFluorine-18rsqb-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer.","volume":"83","author":"Zimny","year":"2001","journal-title":"Gynecol Oncol"},{"key":"R17-3-20210204","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3346\/jkms.2010.25.7.1029","article-title":". Detection of recurrence by 18F-FDG PET in patients with endometrial cancer showing no evidence of disease.","volume":"25","author":"Ryu","year":"2010","journal-title":"J Korean Med Sci"},{"key":"R18-3-20210204","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00259-008-0956-1","article-title":". Performance of integrated FDG-PETcontrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT.","volume":"36","author":"Kitajima","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R19-3-20210204","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12149-007-0087-y","article-title":". Performance of FDG-PETCT in the diagnosis of recurrent endometrial cancer.","volume":"22","author":"Kitajima","year":"2008","journal-title":"Ann Nucl Med"},{"key":"R20-3-20210204","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00259-007-0687-8","article-title":". The clinical impact of (18)FFDG PETCT for the management of recurrent endometrial cancer: correlation with clinical and histological findings.","volume":"35","author":"Chung","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-3-20210204","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00259-006-0251-y","article-title":". Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PETCT in the detection of recurrence.","volume":"34","author":"Sironi","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R22-3-20210204","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1157\/13095169","article-title":". Positron emission tomography with fluordesoxyglucose-F18 in follow-up of endometrial cancer.","volume":"25","author":"Rebollo-Aguirre","year":"2006","journal-title":"Rev Esp Med Nucl"},{"key":"R23-3-20210204","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF02990022","article-title":". Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer.","volume":"17","author":"Saga","year":"2003","journal-title":"Ann Nucl Med"},{"key":"R24-3-20210204","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s00259-002-0878-2","article-title":". Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma.","volume":"29","author":"Belhocine","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R25-3-20210204","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1007\/s00259-010-1440-2","article-title":". Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PETCT studies for the diagnosis of uterine cancer recurrence.","volume":"37","author":"Kitajima","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R26-3-20210204","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":". Cancer statistics, 2007.","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"R27-3-20210204","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":". Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"key":"R31-3-20210204","first-page":"266","article-title":". Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PETCT.","volume":"45","author":"Lerman","year":"2004","journal-title":"J Nucl Med"},{"key":"R32-3-20210204","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1525-1438.2008.01197.x","article-title":". Clinical impact of positron emission tomography or positron emission tomographycomputed tomography in the posttherapy surveillance of endometrial carcinoma: evaluation of 88 patients.","volume":"18","author":"Park","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"R33-3-20210204","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00259-005-0038-6","article-title":". How few cancer cells can be detected by positron emission tomography A frequent question addressed by an in vitro study.","volume":"33","author":"Fischer","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R34-3-20210204","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1148\/radiol.2273020299","article-title":". Effects of nonionic intravenous contrast agents at PETCT imaging: phantom and canine studies.","volume":"227","author":"Nakamoto","year":"2003","journal-title":"Radiology"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0b013e31824d24fa","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:26:16Z","timestamp":1621884376000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201207000-00003"}},"subtitle":["Role of 18-FDG PET\/CT for Detection of Suspected Recurrence"],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0b013e31824d24fa","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}